Share to linkedin
Results from the Phase III clinical trial were presented at the 2019 European Society for Medical Oncology Congress 2019 last weekend. The trial involved 726 postmenopausal women with advanced hormone-receptor positive HER2-breast cancer who had not recieved endocrine therapy in the past, and aimed to see if the treatment could effectively increase lifespan.
“Increasing overall survival is the hardest endpoint to move,” said lead researcher Dr. Dennis Slamon, chair of hematology/oncology and director of Clinical/Translational Research at UCLA’s Jonsson Comprehensive Cancer Center. “We’re also seeing that the time of progression-free survival is the longest yet reported for any of the drugs in this class. And even when patients are off the drug, the effect seems to be long-lasting in terms of the benefit.
Hormone therapy is the standard treatment for most women with such forms of breast cancer. However, research into targeted therapy suggests that hormonal therapy alone may not be best to achieve the desired results in patients. , such as ribociclib, are sometimes used alongside hormone therapy to increase the chance of successful outcomes. Ribociclib is part of a class of CDK4/6 inhibitors.